Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

The company's comparison of its ADCs to Enhertu seems farfetched.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

BeiGene has a strong presence at this year’s AACR, which features several notable duels.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

The 2024 AACR abstract title drop features several noteworthy clinical studies.